US Patent 9,044,475: Apomorphine Sublingual Film Claims, Scope, Expiration, and Competitive Patent Landscape
US Patent 9,044,475 protects a multilayer, non-effervescent sublingual film or strip containing an acid-addition salt of apomorphine, a pH-neutralizing organic base, and a permeation enhancer. The patent is directed to the dosage-form architecture and excipient combination used in sublingual apomorphine delivery, rather than to apomorphine as a molecule.
The core commercial relevance is KYNMOBI, the apomorphine hydrochloride sublingual film developed by Cynapsus Therapeutics and commercialized by Sunovion Pharmaceuticals. The patent is a potential barrier to a competing apomorphine sublingual film that uses the claimed multilayer structure, particle-size range, dose ranges, mucoadhesive polymers, or glycerol monostearate.
What does US Patent 9,044,475 protect?
Claim 1 is the independent composition claim. A competing product must satisfy every limitation of the claim for literal infringement. The claim requires all of the following:
| Claim limitation |
Required element |
| Dosage form |
Pharmaceutical composition in unit dosage form |
| Route |
Sublingual administration |
| Physical form |
Film or strip |
| Layer structure |
At least a first layer and a second layer |
| First layer |
Apomorphine particles containing an acid-addition salt |
| Second layer |
A pH-neutralizing agent that is an organic base |
| Effervescence |
The dosage form must not be effervescent |
| Absorption aid |
The dosage form must contain a permeation enhancer |
The claim does not require apomorphine hydrochloride specifically. Any acid-addition salt of apomorphine can fall within the claim if the other limitations are present. Claim 4 narrows the protected composition to apomorphine hydrochloride.
The claim also does not require a specific organic base or permeation enhancer. This gives claim 1 broader chemical coverage than the dependent claims, subject to claim-construction limits concerning what qualifies as a pH-neutralizing organic base and a permeation enhancer.
How broad is the independent claim?
Claim 1 has meaningful structural breadth but is narrower than a general claim to sublingual apomorphine.
A product outside the claim may avoid infringement by using:
- A tablet, lozenge, liquid, spray, capsule, gel, or orally disintegrating tablet instead of a film or strip.
- A single homogeneous layer rather than separate first and second layers.
- A composition without a pH-neutralizing organic base.
- An inorganic base instead of an organic base, depending on the precise formulation.
- No permeation enhancer.
- A dosage form administered buccally, orally, intranasally, or by injection rather than sublingually.
- An effervescent dosage form, although other patent claims or related patents may address effervescent systems.
A formulation can present risk even if it does not reproduce the marketed KYNMOBI formulation. The claim is functional and structural. It does not require the same manufacturing process, commercial trade dress, polymer, dose, or exact excipient identity.
What dependent claims add to the patent scope?
Claims 2 through 16 progressively narrow the formulation and establish several commercially important fallback positions.
| Claims |
Additional limitation |
| 2 |
Polysaccharide |
| 3 |
Mucoadhesive polymer selected from carboxymethylcellulose, cellulose acetate, ethylcellulose, hydroxyethylcellulose, or hydroxypropylmethylcellulose |
| 4 |
Apomorphine hydrochloride |
| 5 |
Antioxidant |
| 6 |
Glycerol monostearate as the permeation enhancer |
| 7 |
Apomorphine particle size of 1 to 10 micrometers |
| 8 |
Apomorphine hydrochloride particles within the 1 to 10 micrometer range |
| 9 |
2 to 40 mg of an acid-addition salt of apomorphine |
| 10 |
Apomorphine particles in a mucoadhesive polymer |
| 11 |
A third layer between the first and second layers |
| 12 |
12 to 30 mg of an acid-addition salt |
| 13 |
12 +/- 3 mg |
| 14 |
22 +/- 4 mg |
| 15 |
30 +/- 5 mg |
| 16 |
35 +/- 5 mg |
Claims 13 through 16 create dose-specific positions. Their practical coverage is narrower than claim 9, but they may be important in litigation because a commercial product can be analyzed by marketed strength rather than by broad dose-range arguments.
What formulation is most directly exposed?
The highest-risk formulation is a sublingual multilayer film containing:
- Apomorphine hydrochloride;
- Apomorphine particles with an effective particle size of 1 to 10 micrometers;
- A mucoadhesive polymer;
- An organic base in a separate layer;
- A permeation enhancer, particularly glycerol monostearate;
- A dose between 2 and 40 mg;
- A non-effervescent structure.
A product containing every element of claims 7 through 10 would face a substantially narrower but stronger infringement theory than a product analyzed only under claim 1.
The claim set also reaches designs with a third intermediate layer under claim 11. That limitation makes claim 11 narrower, but it can cover multilayer barrier, taste-masking, separation, or controlled-release structures where the third layer is positioned between the apomorphine layer and the base-containing layer.
What does “first layer” and “second layer” mean for infringement?
The claims require a layered film or strip, not merely a formulation containing two excipients. The first layer must comprise the apomorphine particles, and the second layer must comprise the pH-neutralizing organic base.
A single-layer film containing both apomorphine and an organic base may fall outside the literal language of claim 1 because the claim allocates those components to different layers. A two-layer product may still infringe if the layers are physically distinct even when manufactured by co-extrusion, lamination, sequential casting, or another process.
The patent does not require the first and second layers to have equal thickness, identical polymer composition, or a particular order of dissolution. Those limitations should not be added to the claim unless required by the intrinsic record or prosecution history.
What particle-size range is protected?
Claims 7 and 8 cover apomorphine particles having an effective particle size from 1 micrometer to 10 micrometers.
The range is a dependent limitation and does not narrow claim 1 unless a product is analyzed under claims 7 or 8. A product with particles outside that range may still be evaluated under claim 1, because claim 1 does not state a particle-size requirement.
Particle-size testing can become a significant evidentiary issue. The phrase “effective particle size” may depend on the analytical method, sample preparation, particle aggregation, and whether the measurement is based on a volume, number, or other distribution. A generic or follow-on developer would need consistent analytical data across batches.
What dose ranges are protected?
Claim 9 covers 2 to 40 mg of an acid-addition salt of apomorphine. Claims 12 through 16 create narrower dose positions:
| Claim |
Dose range |
| 9 |
2 to 40 mg |
| 12 |
12 to 30 mg |
| 13 |
9 to 15 mg |
| 14 |
18 to 26 mg |
| 15 |
25 to 35 mg |
| 16 |
30 to 40 mg |
The narrower ranges overlap. For example, a 12 mg product can fall within claims 9, 12, and 13. A 30 mg product can fall within claims 9, 12, 14, 15, and 16, depending on how the stated tolerances are applied.
The use of “acid addition salt” means dose analysis may require attention to whether the claimed amount refers to the salt mass or the apomorphine active moiety. The claim language states the amount of the acid-addition salt, which can produce different numerical results than an active-moiety calculation.
When does US Patent 9,044,475 expire?
The patent issued on May 26, 2015, from an application directed to sublingual apomorphine compositions. Public patent records identify a July 20, 2011 priority date and a July 20, 2012 nonprovisional filing date for the relevant patent family. The ordinary patent term is therefore expected to run approximately 20 years from the nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
| Event |
Date |
| Earliest reported priority date |
July 20, 2011 |
| US nonprovisional filing date |
July 20, 2012 |
| US publication |
January 24, 2013 |
| Patent grant |
May 26, 2015 |
| Nominal term from filing |
July 20, 2032 |
| Relevant commercial product |
KYNMOBI |
The operative expiration date should be taken from the USPTO Patent Center term calculation and any FDA Orange Book listing. The priority date does not itself determine the expiration date.
What is the FDA and Orange Book status associated with the patent?
The relevant FDA product is KYNMOBI, an apomorphine hydrochloride sublingual film approved for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease. FDA approved KYNMOBI in May 2020 under an NDA held by Sunovion Pharmaceuticals.[1]
KYNMOBI is a small-molecule drug product, not a biologic. A competing applicant would generally pursue an abbreviated new drug application, if it could satisfy the applicable pharmaceutical-equivalence and bioequivalence requirements, or a 505(b)(2) application where formulation or clinical differences prevent a conventional ANDA pathway.
The FDA approval does not establish that every patent in the broader apomorphine film family is listed for every KYNMOBI strength. Orange Book listing is product- and NDA-specific. A patent can create infringement exposure even when it is not listed in the Orange Book, while an Orange Book-listed patent can trigger ANDA certification and litigation consequences.
What Paragraph IV risks exist?
A generic applicant seeking approval before patent expiration could make a Paragraph IV certification against an Orange Book-listed patent. For US Patent 9,044,475, the principal Paragraph IV arguments would likely focus on:
- Whether the proposed product is actually a film or strip.
- Whether it has physically separate first and second layers.
- Whether the base is a pH-neutralizing organic base.
- Whether the product contains a permeation enhancer.
- Whether the product is non-effervescent.
- Whether the selected apomorphine salt falls within “acid addition salt.”
- Whether particle size and dose limitations are met for the dependent claims.
A proposed product could avoid some dependent claims while still facing claim 1. Conversely, a design-around that removes the layered arrangement or permeation enhancer may reduce literal infringement risk without eliminating all regulatory or patent risks associated with other family members.
A first-filed substantially complete ANDA with a Paragraph IV certification may qualify for 180-day generic exclusivity under the Hatch-Waxman framework if statutory conditions are satisfied. The patent itself does not guarantee a 30-month stay. That consequence depends on the timing and scope of any listed patent litigation.
Which companies are associated with the patent and product?
| Company |
Role |
| Cynapsus Therapeutics |
Original developer of the sublingual apomorphine program |
| Sunovion Pharmaceuticals |
Acquired Cynapsus and commercialized KYNMOBI |
| Sumitomo Pharma |
Parent organization associated with Sunovion operations |
| Generic developers |
Potential ANDA applicants for apomorphine sublingual products |
The commercial landscape is narrower than the injectable apomorphine market because sublingual film delivery requires control of taste, mucosal adhesion, dose uniformity, particle size, dissolution, absorption, and local tolerability.
How does this patent compare with competing apomorphine delivery approaches?
| Delivery approach |
Relevance to US 9,044,475 |
Main development issue |
| Sublingual film or strip |
Directly within the patent’s technical field |
Layer architecture and excipient selection |
| Sublingual tablet |
Generally outside the literal film-or-strip limitation |
Bioequivalence and absorption profile |
| Subcutaneous injection |
Outside the claim scope |
Injection burden and device requirements |
| Subcutaneous infusion |
Outside the claim scope |
Pump and tolerability requirements |
| Buccal film |
Potentially outside the sublingual limitation |
Route-of-administration classification |
| Oral tablet or capsule |
Outside the claim scope |
Low or variable apomorphine absorption |
| Nasal delivery |
Outside the claim scope |
Nasal tolerability and dose reproducibility |
A competing sublingual film presents the greatest direct infringement risk. A sublingual tablet may have lower risk under this patent but can encounter separate formulation, method-of-use, regulatory, and freedom-to-operate barriers.
How strong is the patent estate?
US 9,044,475 has a commercially relevant claim structure because claim 1 combines multiple product attributes that are likely to be present in a sophisticated sublingual apomorphine film:
- Separate layers;
- Acid-addition apomorphine salt;
- Organic pH-neutralizing agent;
- Permeation enhancer;
- Non-effervescent delivery.
The estate is stronger against close copies of the patented formulation than against alternative delivery systems. Its practical strength depends on claim construction, prosecution-history estoppel, validity challenges concerning prior art, and whether the commercial product or a proposed generic meets the layer and excipient limitations.
The most vulnerable technical issues for validity and enforcement analysis are likely to include:
- Prior art on sublingual apomorphine;
- Prior art on multilayer oral films;
- Known use of organic bases to adjust local pH;
- Known permeation enhancers in mucosal delivery;
- Obviousness combinations involving apomorphine salt, film polymers, particle size, and dose selection;
- Enablement and written-description support across the full scope of claim 1.
What manufacturing and intellectual-property barriers remain?
The formulation claims create barriers beyond the active ingredient. A follow-on developer must manage:
- Apomorphine oxidation and chemical stability;
- Uniform distribution of micronized particles;
- Layer-to-layer adhesion;
- Separation of acidic and basic excipients during storage;
- Film mechanical strength;
- Sublingual disintegration;
- Taste and local irritation;
- Dose uniformity at low film mass;
- Packaging protection from oxygen and moisture;
- Reproducible permeation enhancement.
Manufacturing know-how may be protected separately through trade secrets, process patents, or additional formulation patents. A design-around that avoids US 9,044,475 can still encounter other patents covering composition, process, dosing, treatment method, packaging, or related delivery technologies.
Key Takeaways
- US 9,044,475 is directed to a non-effervescent multilayer sublingual apomorphine film or strip.
- Claim 1 requires an apomorphine acid-addition salt, a pH-neutralizing organic base in a separate layer, and a permeation enhancer.
- Apomorphine hydrochloride is specifically covered by claim 4 and claims 8 through 16.
- Claims 7 and 8 cover apomorphine particles with an effective particle size of 1 to 10 micrometers.
- Claims 9 and 12 through 16 cover dose ranges from 2 to 40 mg, including 12 mg, 22 mg, 30 mg, and 35 mg products.
- The nominal term runs to approximately July 20, 2032, subject to USPTO term adjustment and any applicable extension.
- The greatest direct infringement risk applies to a KYNMOBI-like multilayer sublingual film.
- Sublingual tablets, injections, infusions, nasal products, and single-layer films may avoid literal infringement of claim 1, but they require separate freedom-to-operate analysis.
- The relevant regulatory pathway for a small-molecule follow-on product is generally an ANDA or, where appropriate, a 505(b)(2) application.
- Biosimilar analysis does not apply because apomorphine is a small molecule, not a biologic.
FAQs About US Patent 9,044,475
Does US 9,044,475 cover apomorphine hydrochloride generally?
No. The claims cover apomorphine hydrochloride in a specified sublingual film or strip architecture with additional layer, base, and permeation-enhancer requirements. Injectable and conventional oral apomorphine products are outside the literal composition defined by claim 1.
Does a single-layer apomorphine film infringe claim 1?
A single-layer film generally lacks the separately recited first and second layers. It may avoid literal infringement of claim 1, although other claims or related patents could present separate risk.
Is glycerol monostearate required by the independent claim?
No. Glycerol monostearate is required only by claim 6. Claim 1 broadly requires a permeation enhancer without naming a particular enhancer.
Does the patent cover a 40 mg apomorphine film?
Claim 9 covers 2 to 40 mg, subject to the other limitations of the claim. A 40 mg product may also implicate claim 16 if it falls within the stated 30 +/- 5 mg range.
Is there a biosimilar pathway for KYNMOBI?
No. KYNMOBI contains apomorphine hydrochloride, a small-molecule active ingredient. A follow-on applicant would generally evaluate the ANDA or 505(b)(2) pathway rather than a biosimilar application.
References
- U.S. Food and Drug Administration. (2020). KYNMOBI (apomorphine hydrochloride) sublingual film prescribing information. FDA.
- U.S. Patent and Trademark Office. (2015). United States Patent No. 9,044,475: Sublingual apomorphine compositions. USPTO.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
- U.S. Patent and Trademark Office. (n.d.). Patent Center: Patent term and application history records. USPTO.
